| 24.07 12:56 | dpa-AFX: Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails |
| 24.07 12:35 | dpa-AFX: *SAGE THERAPEUTICS, BIOGEN: TOPLINE RESULTS FROM PHASE 2 KINETIC 2 STUDY OF SAGE-324 FAILS TO MEET END POINT |
| 02.07 15:47 | dpa-AFX: *BIOGEN CLOSES ACQUISITION OF HUMAN IMMUNOLOGY BIOSCIENCES |
| 02.07 15:16 | dpa-AFX: GNW-Adhoc: Biogen Completes Acquisition of Human Immunology Biosciences |
| 28.06 01:39 | dpa-AFX: GNW-Adhoc: "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| 24.06 14:22 | dpa-AFX: Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications |
| 24.06 13:57 | dpa-AFX: *BIOGEN'S TOFIDENCE BIOSIMILAR RECEIVES EC APPROVAL FOR MULTIPLE INDICATIONS INCL. COVID-19 TREATMENT |
| 24.06 13:30 | dpa-AFX: GNW-Adhoc: TOFIDENCET (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union |
| 10.06 07:07 | dpa-AFX: *BIOGEN SAYS FDA ACCEPTS EISAI'S SBLA FOR MONTHLY LECANEMAB-IRMB IV MAINTENANCE DOSING |
| 10.06 02:48 | dpa-AFX: Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment |
| 10.06 01:37 | dpa-AFX: GNW-Adhoc: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| 06.06 12:37 | Italienische Wettbewerbsbehörde nimmt vier Pharmakonzerne ins Visier |
| 31.05 04:16 | dpa-AFX: Biogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis |
| 30.05 22:51 | dpa-AFX: GNW-Adhoc: Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS |
| 22.05 22:14 | MÄRKTE USA/Etwas leichter - Fed weiter besorgt über hohe Inflation |
| 22.05 18:02 | MÄRKTE USA/Wall Street wenig bewegt vor Fed-Protokoll und Nvidia |
| 22.05 15:43 | MÄRKTE USA/Börsen treten auf der Stelle - Fed-Protokoll und Nvidia im Fokus |
| 22.05 14:11 | dpa-AFX: Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln |
| 22.05 14:01 | dpa-AFX: *BIOGEN EXPECTS TO CLOSE HUMAN IMMUNOLOGY BIOSCIENCES DEAL IN Q3 |
| 22.05 14:00 | dpa-AFX: *BIOGEN TO BUY HUMAN IMMUNOLOGY BIOSCIENCES FOR $1.15 BLN UPFRONT & UP TO $650MLN MILESTONE PAYMENTS |
|
|
